Canakinumab, a fully human IL-1β neutralizing monoclonal antibody, emerged as a potentially more viable candidate both because of the specific role IL-1β signaling plays in potentiating atherosclerosis and because it would leave host immune function via IL-1α intact. The gene discussed is IL1B; the disease is atherosclerosis.